Top

Published in:

01-07-2015 | Original Paper

Higher plasma levels of MR-pro-atrial natriuretic peptide are linked to less anxiety: results from the observational DIAST-CHF study

Authors: Thomas Meyer, Christoph Herrrmann-Lingen, Mira-Lynn Chavanon, Kathleen Nolte, Caroline Anna Pasedach, Lutz Binder, Burkert Pieske, Gerd Hasenfuss, Rolf Wachter, Frank Edelmann

Published in: Clinical Research in Cardiology | Issue 7/2015

Abstract

Aims

Growing evidence suggests that natriuretic peptides play a role in the neurobiology of anxiety. In the present study, we investigated whether in patients with cardiovascular risk factors higher plasma levels of natriuretic peptides are linked to reduced anxiety.

Methods

A total of 1,360 patients from the observational DIAST-CHF study (mean age 65.9 ± 8.2 years, 48.7 % males, mean left ventricular ejection fraction 60.0 ± 8.2 %) with risk factors for diastolic heart failure were included. Study participants underwent physical examination, echocardiography, and assessment of anxiety using the Hospital Anxiety and Depression Scale (HADS). In addition, plasma concentrations of natriuretic peptides were measured.

Results

Among the total study population, there were n = 117 patients (8.6 %) with HADS anxiety scores above the cut-off (≥11) suggestive of clinically relevant anxiety. In bivariate analyses, we found a significant inverse association between elevated HADS anxiety and log-transformed mid-regional pro-atrial natriuretic peptide (MR-proANP) (p < 0.001) and amino-terminal pro-brain natriuretic peptide (NT-proBNP) (p = 0.008). Logistic regression models adjusted for sex, age, body mass index, and Framingham score confirmed that plasma MR-proANP (exp(β) = 0.35, 95 % confidence interval [95 % CI] 0.14–0.92, p = 0.032) concentrations were significantly and inversely associated with clinically relevant anxiety, while NT-proBNP (exp(β) = 0.67, 95 % CI 0.41–1.07, p = 0.094) failed to reach the significance level in independently predicting anxiety.

Conclusions

In our study population of outpatients with cardiovascular risk factors, plasma concentrations of MR-proANP were negatively and independently related to clinically relevant anxiety. Further investigations are required to search for possible anxiolytic effects of this circulating natriuretic peptide in medical outpatients with cardiovascular risk factors for diastolic dysfunction.

Nishikimi T, Kuwahara K, Nakao K (2011) Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. J Cardiol 57(2):131–140PubMedCrossRef

Clerico A, Emdin M (2004) Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 50(1):33–50PubMedCrossRef

Doust JA, Glasziou PP, Pietrzak E, Dobson AJ (2004) A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med 164(18):1978–1984PubMedCrossRef

Gruson D, Rousseau MF, Ahn S, Van Linden F, Thys F, Ketelslegers JM, Verschuren F (2008) Accuracy of N-terminal-pro-atrial natriuretic peptide in patients admitted to emergency department. Scand J Clin Lab Invest 68(5):410–414PubMedCrossRef

Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS (2004) Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350(7):655–663PubMedCrossRef

Giannakoulas G, Dimopoulos K, Bolger AP, Tay EL, Inuzuka R, Bedard E, Davos C, Swan L, Gatzoulis MA (2010) Usefulness of natriuretic peptide levels to predict mortality in adults with congenital heart disease. Am J Cardiol 105(6):869–873PubMedCrossRef

Volpe M, Francia P, Tocci G, Rubattu S, Cangianiello S, Elena Rao MA, Trimarco B, Condorelli M (2010) Prediction of long-term survival in chronic heart failure by multiple biomarker assessment: a 15-year prospective follow-up study. Clin Cardiol 33(11):700–707PubMedCrossRef

Lauridsen BK, Iversen K, Hunter I, Bay M, Kirk V, Nielsen OW, Nielsen H, Boesgaard S, Køber L, Goetze JP (2013) ProANP plasma measurement predicts all-cause mortality in acutely hospitalised patients: a cohort study. BMJ Open 3(11):e003288PubMedCentralPubMedCrossRef

Leistner DM, Klotsche J, Pieper L, Palm S, Stalla GK, Lehnert H, Silber S, März W, Wittchen HU, Zeiher AM (2013) Prognostic value of NT-pro-BNP and hs-CRP for risk stratification in primary care: results from the population-based DETECT study. Clin Res Cardiol 102(4):259–268PubMedCrossRef

10.

Kara K, Mahabadi AA, Geisel MH, Lehmann N, Kälsch H, Bauer M, Neumann T, Dragano N, Moebus S, Möhlenkamp S, Jöckel KH, Erbel R (2014) B-type natriuretic peptide: distribution in the general population and the association with major cardiovascular and coronary events—the Heinz Nixdorf Recall Study. Clin Res Cardiol 103(2):125–132PubMedCrossRef

11.

Falcão LM, Pinto F, Ravara L, van Zwieten PA (2004) BNP and ANP as diagnostic and predictive markers in heart failure with left ventricular systolic dysfunction. J Renin Angiotensin Aldosterone Syst 5(3):121–129PubMedCrossRef

12.

Lindberg S, Jensen JS, Pedersen SH, Galatius S, Goetze JP, Mogelvang R (2014) MR-proANP improves prediction of mortality and cardiovascular events in patients with STEMI. Eur J Prev Cardiol [Epub ahead of print]

13.

Squire IB, O’Brien RJ, Demme B, Davies JE, Ng LL (2004) N-terminal pro-atrial natriuretic peptide (N-ANP) and N-terminal pro-B-type natriuretic peptide (N-BNP) in the prediction of death and heart failure in unselected patients following acute myocardial infarction. Clin Sci (Lond) 107(3):309–316CrossRef

14.

Bíró E, Tóth G, Telegdy G (1996) Effect of receptor blockers on brain natriuretic peptide and C-type natriuretic peptide caused anxiolytic state in rats. Neuropeptides 30(1):59–65PubMedCrossRef

15.

Ströhle A, Holsboer F (2003) Stress responsive neurohormones in depression and anxiety. Pharmacopsychiatry 36(Supp3):207–214

16.

Demiralay C, Jahn H, Kellner M, Yassouridis A, Wiedemann K (2010) Influence of exogenous atrial natriuretic peptide on the nocturnal hypothalamic-pituitary-adrenal axis and sleep in healthy men. Psychoneuroendocrinology 35(10):1438–1445PubMedCrossRef

17.

Ströhle A, Kellner M, Holsboer F, Wiedemann K (2001) Anxiolytic activity of atrial natriuretic peptide in patients with panic disorder. Am J Psychiatry 158(9):1514–1516PubMedCrossRef

18.

Wiedemann K, Jahn H, Kellner M (2000) Effects of natriuretic peptides upon hypothalamo-pituitary-adrenocortical system activity and anxiety behaviour. Exp Clin Endocrinol Diabetes 108(1):5–13PubMed

19.

Wiedemann K, Jahn H, Yassouridis A, Kellner M (2001) Anxiolytic-like effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings. Arch Gen Psychiatry 58(4):371–377PubMedCrossRef

20.

Murberg TA, Bru E, Svebak S, Aarsland T, Dickstein K (1997) The role of objective health indicators and neuroticism in perceived health and psychological well-being among patients with chronic heart failure. Personal Individ Differ 22(6):867–875CrossRef

21.

Herrmann-Lingen C, Binder L, Klinge M, Sander J, Schenker W, Beyermann B, von Lewinski D, Pieske B (2003) High plasma levels of N-terminal pro-atrial natriuretic peptide associated with low anxiety in severe heart failure. Psychosom Med 65(4):517–522PubMedCrossRef

22.

Edelmann F, Stahrenberg R, Polzin F, Kockskämper A, Düngen HD, Duvinage A, Binder L, Kunde J, Scherer M, Gelbrich G, Hasenfuss G, Pieske B, Wachter R, Herrmann-Lingen C (2011) Impaired physical quality of life in patients with diastolic dysfunction associates more strongly with neurohumoral activation than with echocardiographic parameters: quality of life in diastolic dysfunction. Am Heart J 161(4):797–804PubMedCrossRef

23.

Stahrenberg R, Edelmann F, Mende M, Kockskämper A, Düngen HD, Lüers C, Binder L, Herrmann-Lingen C, Gelbrich G, Hasenfuss G, Pieske B, Wachter R (2010) The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. Eur J Heart Fail 12(12):1309–1316PubMedCentralPubMedCrossRef

24.

Stahrenberg R, Edelmann F, Mende M, Kockskämper A, Düngen HD, Scherer M, Kochen MM, Binder L, Herrmann-Lingen C, Schönbrunn L, Gelbrich G, Hasenfuss G, Pieske B, Wachter R (2010) Association of glucose metabolism with diastolic function along the diabetic continuum. Diabetologia 53(7):1331–1340PubMedCentralPubMedCrossRef

25.

Ho KK, Pinsky JL, Kannel WB, Levy D (1993) The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 22(4 Suppl A):6A–13APubMedCrossRef

26.

Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361–370PubMedCrossRef

27.

Herrmann C (1997) International experiences with the Hospital Anxiety and Depression Scale. A review of validation data and clinical results. J Psychosom Res 42(1):17–41PubMedCrossRef

28.

Bjelland I, Dahl AA, Haug TT, Neckelmann D (2002) The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 52(2):69–77PubMedCrossRef

29.

Prontera C, Emdin M, Zucchelli GC, Ripoli A, Passino C, Clerico A (2004) Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide. Clin Chem Lab Med 42(1):37–44PubMedCrossRef

30.

Clerico A, Prontera C, Emdin M, Passino C, Storti S, Poletti R, Zyw L, Zucchelli GC (2005) Analytical performance and diagnostic accuracy of immunometric assays for the measurement of plasma B-type natriuretic peptide (BNP) and N-terminal proBNP. Clin Chem 51(2):445–447PubMedCrossRef

31.

Wu AH, Packer M, Smith A, Bijou R, Fink D, Mair J, Wallentin L, Johnston N, Feldcamp CS, Haverstick DM, Ahnadi CE, Grant A, Despres N, Bluestein B, Ghani F (2004) Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study. Clin Chem 50(5):867–873PubMedCrossRef

32.

Morgenthaler NG, Struck J, Thomas B, Bergmann A (2004) Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 50(1):234–236PubMedCrossRef

33.

Gegenhuber A, Struck J, Poelz W, Pacher R, Morgenthaler NG, Bergmann A, Haltmayer M, Mueller T (2006) Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNP. Clin Chem 52(5):827–831PubMedCrossRef

34.

Potocki M, Breidthardt T, Reichlin T, Hartwiger S, Morgenthaler NG, Bergmann A, Noveanu M, Freidank H, Taegtmeyer AB, Wetzel K, Boldanova T, Stelzig C, Bingisser R, Christ M, Mueller C (2010) Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure. J Intern Med 267(1):119–129PubMedCrossRef

35.

Pająk A, Jankowski P, Kotseva K, Heidrich J, de Smedt D, De Bacquer D, EUROASPIRE Study Group (2013) Depression, anxiety, and risk factor control in patients after hospitalization for coronary heart disease: the EUROASPIRE III Study. Eur J Prev Cardiol 20(2):331–340PubMedCrossRef

36.

Brouwers C, Spindler H, Larsen ML, Eiskær H, Videbæk L, Pedersen MS, Aagard B, Pedersen SS (2012) Association between psychological measures and brain natriuretic peptide in heart failure patients. Scand Cardiovasc J 46(3):154–162PubMedCrossRef

37.

Bidzseranova A, Gueron J, Tóth G, Penke B, Varga J, Telegdy G (1992) Behavioral effects of atrial and brain natriuretic peptides in rats. Neuroreport 3(3):283–285PubMedCrossRef

38.

Bhattacharya SK, Chakrabarti A, Sandler M, Glover V (1996) Anxiolytic activity of intraventricularly administered atrial natriuretic peptide in the rat. Neuropsychopharmacology 15(2):199–206PubMedCrossRef

39.

Langub MC Jr, Watson RE Jr, Herman JP (1995) Distribution of natriuretic peptide precursor mRNAs in the rat brain. J Comp Neurol 356(2):183–199PubMedCrossRef

40.

Seier FE, Kellner M, Yassouridis A, Heese R, Strian F, Wiedemann K (1997) Autonomic reactivity and hormonal secretion in lactate-induced panic attacks. Am J Physiol 272(6 Pt 2):H2630–H2638PubMed

41.

Lyu T, Zhao Y, Zhang T, Zhou W, Yang F, Ge H, Ding S, Pu J, He B (2014) Natriuretic peptides as an adjunctive treatment for acute myocardial infarction: insights from the meta-analysis of 1,389 patients from 20 trials. Int Heart J 55(1):8–16PubMedCrossRef

Title: Higher plasma levels of MR-pro-atrial natriuretic peptide are linked to less anxiety: results from the observational DIAST-CHF study
Authors: Thomas Meyer
Christoph Herrrmann-Lingen
Mira-Lynn Chavanon
Kathleen Nolte
Caroline Anna Pasedach
Lutz Binder
Burkert Pieske
Gerd Hasenfuss
Rolf Wachter
Frank Edelmann
Publication date: 01-07-2015
Publisher: Springer Berlin Heidelberg
Published in: Clinical Research in Cardiology / Issue 7/2015
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-015-0820-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Higher plasma levels of MR-pro-atrial natriuretic peptide are linked to less anxiety: results from the observational DIAST-CHF study

Abstract

Aims

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Aims

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2015

Tako-tsubo cardiomyopathy in two sisters: a chance finding or familial predisposition?

Renal sympathetic denervation for treatment of ventricular arrhythmias: a review on current experimental and clinical findings

Economic implications of intra-aortic balloon support for myocardial infarction with cardiogenic shock: an analysis from the IABP-SHOCK II-trial

Electrophysiological and electrocardiographic predictors of ventricular arrhythmias originating from the left ventricular outflow tract within and below the coronary sinus cusps

Assessment of global longitudinal strain using standardized myocardial deformation imaging: a modality independent software approach

Chronotropic incompetence presenting as sudden sinus slowing during exercise stress test: the pathophysiological mechanisms

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page